Arcus Biosciences (RCUS) Cash from Investing Activities Growth (1y) (2018 - 2026)
Arcus Biosciences (RCUS) Cash from Investing Activities Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7,936.68% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 26.37% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -157.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -89.24% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -62.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.04% |
| Mar 31, 2026 | 256.25% |
| Dec 31, 2025 | -456.86% |
| Sep 30, 2025 | 372.41% |
| Jun 30, 2025 | 117.46% |
| Mar 31, 2025 | 118.93% |
| Dec 31, 2024 | 82.14% |
| Sep 30, 2024 | -363.64% |
| Jun 30, 2024 | 142.31% |
| Mar 31, 2024 | -231.01% |
| Dec 31, 2023 | -40.43% |
| Sep 30, 2023 | -52.17% |
| Jun 30, 2023 | 112.09% |
| Mar 31, 2023 | 148.13% |
| Dec 31, 2022 | 150.24% |
| Sep 30, 2022 | 125.96% |
| Jun 30, 2022 | -7,259.51% |
| Mar 31, 2022 | -526.57% |
| Dec 31, 2021 | 13,710.29% |
| Sep 30, 2021 | 77.11% |